Programme - BPA 2020
BioProcessing Asia 2020 follows in the footsteps of the three previous highly successful BPA Conferences and moves to Singapore and the largest biotechnology cluster in the Asia/Asia-Pacific region. The conference addresses the most important issues facing the development of a dynamic, vibrant bioprocessing industry in Asia.
Six half-day Oral Sessions and an interactive Poster Session will provide conference participants with the latest innovations in bioprocessing and direct access to key international opinion leaders in the field.
The rapidly changing demographics in Asia generate an increasing demand for all types of affordable biopharmaceutical products from prevention to treatment. To a large extent, the ability to satisfy patient needs will rely on the ability of the Asian biopharmaceutical industry to research, develop and manufacture safe and efficacious products. For this, a dynamic and innovative R&D culture is required in concert with the development of high yielding, reliable, reproducible and sustainable processes.
BioProcessing Asia 2020 opens on Monday 26 October 2020 with a Keynote Address from a well-known opinion leader in the biopharmaceutical space.
The six Scientific Sessions of 5 talks each on Tuesday – Thursday cover all the different biological product modalities with a special look at gene and cell therapies. Sessions have a science and technology focus on process development and a pragmatic and reality-based look at new advances that contribute to improved efficiency and product quality. A final, forward-looking session will address the state of digitalization in the industry. A Poster Session will enable attendees to discuss the latest issues with presenters.
Monday 26 October 2020
Keynote Address - To be announced
Tuesday 27 October 2020
Session 1: Diseases, treatments and the future of biopharmaceuticals
Arindam Bose, Former Vice-President, Biotherapeutics External Affairs & Biosimilars Strategy, Pfizer, Independent Biotechnology & Bioprocessing Consultant, AbiologicsB, LLC, Stonington, USA
Say Kong Ng, Senior Scientist, Bioprocessing Technology Institute, A*STAR, Agency for Science, Technology and Singapore-MIT Alliance, National University of Singapore, Singapore.
Session 2: The use of smart process development to improve process efficiency and product quality
Stefan Hepbildikler, Director, Technology Pharma Bioprocess Development, Roche Pharmaceuticals, Munich, Germany
Min Zhu, Director, Protein Science, Boehringer Ingelheim, Fremont, USA
Wednesday 28 October 2020
Session 3: A reality check on flexible, integrated and continuous biomanufacturing
Wei (Heidi) Gong, Senior Director of Bridge Manufacturing, Shanghai Henlius Biopharmaceutical Co., Ltd., Shanghai, China
Ekta Mahajan, Program Director, Pharma Technical Regulatory, Genentech, a Member of the Roche Group, South San Francisco, USA
Session 4: Regulatory development in Asia
Dorothee Ambrosius, Former Head of CMC Strategy Biologicals, Boehringer Ingelheim, Biberach, Germany
Scott Wheelwright, Co-founder and Principal Consultant, Complya Asia, Co. Ltd., Suzhou, China
Thursday 29 October 2020
Session 5: Cell and gene therapy: mapping innovation required for manufacturing
Hari Pujar, Chief Technology Officer, Spark Therapeutics, Inc., Philadelphia, USA
Mats Lundgren, Customer Applications Director, GE Healthcare Life Sciences, Uppsala, Sweden
Session 6: Demystifying Biopharma 4.0
Anurag Rathore, Professor, Department of Chemical Engineering, Indian Institute of Technology, New Delhi, India
Uwe Gottschalk, Chief Scientific Officer, Lonza, Switzerland
Session 7: Poster Session
Linda Hwee-Lin Lua, Professor & Protein Expression Facility Director, University of Queensland, Brisbane, Australia
Balaji Somasundaram, Strategy and Operations Manager, Protein Expression Facility, University of Queensland, Brisbane, Australia